A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Public ClinicalTrials.gov record NCT00585195. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.
Study identification
- NCT ID
- NCT00585195
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 596 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 19, 2006 (Actual)
- Primary completion
- Jul 30, 2020 (Actual)
- Completion
- Jan 19, 2022 (Actual)
- Last update posted
- Feb 8, 2023
2006 – 2022
United States locations
- U.S. sites
- 24
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Irvine Medical Center | Orange | California | 92868-3201 | — |
| University of Colorado Hospital/ Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Ophthalmic Consultants of Boston Inc. | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Center | Boston | Massachusetts | 02215 | — |
| Joslin Beetham Eye Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Kresge Eye Institute | Detroit | Michigan | 48201 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10022 | — |
| Memorial Sloan Kettering Cancer Center: Breast and Imaging Center | New York | New York | 10065 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| UNC Hospitals | Chapel Hill | North Carolina | 27599-7600 | — |
| The James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | — |
| Ohio State Eye and Ear Institute | Columbus | Ohio | 43212 | — |
| The Ohio State University Martha Morehouse Medical Plaza | Columbus | Ohio | 43221 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| Vanderbilt Eye Institute | Nashville | Tennessee | 37232 | — |
| The University of Vermont Medical Center | Burlington | Vermont | 05401 | — |
| The University of Vermont Cancer Center | Burlington | Vermont | 05405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00585195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00585195 live on ClinicalTrials.gov.